Hangzhou-based biopharmaceutical company Adlai Nortye Biopharma announced that it has raised a US$53 million series B round from Matrix Partners China and other investors.
UNLOCK DATA
Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech
Want to read this important story?
Access thousands of news articles and data posts over the past 9 years!
Already have an account or paid subscription? Log in
